RAC - Race Oncology

access said:

Could not see my comment re December entry so here I go again.

Since posting my December selection I have read an item that may indicate the news I was expecting this month may not be ready for posting until possibly January. I still feel there will be a build up in December.

Following a recently completed 2 year investigation with Monash University it looks like RAC will be patenting the results of a range of other unique discoveries found in the investigation. There will probably not be time to bring these new discoveries to trials before the company or its principal product (Bisantrine) is sold in about 4 or 5 years time but they will add a lot of extra value to RAC.

Click to expand...

• Human ethics regulatory package submitted for Race’s Phase 1 trial in solid tumour patients using RC220 bisantrene, with up to 10 additional sites to follow
• Will study RC220 in combination with doxorubicin in adult cancer patients
• First patient recruitment is expected to occur in Q1 2025.

JohnDe said:

Anything to do with this -

Race Submits Human Ethics Application Package for RC220
Phase 1 Solid Tumour Trial

• Human ethics regulatory package submitted for Race’s Phase 1 trial in solid tumour patients using RC220 bisantrene, with up to 10 additional sites to follow
• Will study RC220 in combination with doxorubicin in adult cancer patients
• First patient recruitment is expected to occur in Q1 2025.

Click to expand...